The British Journal of Cardiology

AUGUST 6, 2024

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce cardiovascular rehospitalisation in heart failure with reduced ejection fraction (HFrEF) patients. A retrospective study of four hospitals in England involving 184 patients with HFrEF exacerbations between March 2021 and June 2022 was performed.

Inpatient 52

Inpatient Heart Failure Diabetes Hospital 52

Cardiovascular Diabetology

JULY 9, 2024

To adapt risk prediction equations for myocardial infarction (MI), stroke, and heart failure (HF) among patients with type 2 diabetes in real-world settings using cross-institutional electronic health records.

Myocardial Infarction 52

Myocardial Infarction Diabetes Heart Failure Outcomes 52

Circulation: Cardiovascular Quality & Outcomes

FEBRUARY 8, 2024

Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. Background:Patients with type 2 diabetes are at risk of heart failure hospitalization. Accounting for all-cause mortality, we obtained the incidence for heart failure hospitalization at 5 years follow-up; overall and in each SDI group.

Heart Failure 40

Heart Failure Diabetes Outpatient Hospital 40

Hypertension Journal

NOVEMBER 22, 2023

BACKGROUND:Diabetes is an important risk factor for heart failure (HF) and is associated with left ventricular (LV) diastolic dysfunction. However, diabetic comorbid conditions, such as nocturnal hypertension, as predictors of diastolic dysfunction are not known in the absence of an HF period. Hypertension, Ahead of Print.

Hypertension 40

Hypertension Heart Failure Diabetes Risk Factors 40

European Journal of Heart Failure

SEPTEMBER 26, 2023

Abstract Diagnosing heart failure is often difficult due to the non-specific nature of symptoms, which can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been recognized as important biomarkers for diagnosing heart failure. Use of this acronym would enable the early diagnosis of heart failure.

Heart Failure 40

Heart Failure Coronary Artery Disease Outpatient Document 40

Open Heart

MAY 23, 2024

Background and aims Pre-eclampsia complicates 3–5% of pregnancies worldwide and is associated with adverse outcomes for the mother and the offspring. Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes.

Heart Disease 98

Heart Disease Heart Failure Risk Factors Obesity 98

Heart BMJ

DECEMBER 15, 2023

Aims Identifying clinical and echocardiographic parameters associated with improvement in systolic function in outpatients with heart failure with reduced ejection fraction (HFrEF) could lead to more targeted treatment improving systolic function and outcome. Beta-coefficients (β-coef) are standardised. to 7.51, p=0.006).

Heart Failure 45

Heart Failure Outpatient Tricuspid Cardiomyopathy 45

American College of Cardiology

AUGUST 30, 2024

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing serious COVID-19-related events and improving heart failure (HF) symptoms, according to six new substudies published in JACC.

COVID-19 40

COVID-19 Obesity Heart Failure Outcomes 40

Journal of Cardiovascular Pharmacology

NOVEMBER 14, 2023

Abstract: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with heart failure (HF). However, studies examining their benefits exclusively in nondiabetic patients on various HF outcomes are limited. and a 95% CI of 0.84 to 1.07 (p=0.37). Copyright © 2023 The Author(s).

Heart Failure 40

Heart Failure Outcomes Hospital Diabetes 40

Heart BMJ

JANUARY 10, 2024

Objective Identification of patients at risk of adverse outcome from heart failure (HF) at an early stage is a priority. Primary outcome was a composite of first hospitalisation for HF or all-cause mortality. Log-transformed GDF-15 was the strongest predictor of outcome (HR 2.12, 95% CI 1.71

Heart Failure 52

Heart Failure Biomarkers Outcomes Diabetes 52

European Journal of Heart Failure

DECEMBER 7, 2023

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Obesity was associated with more first and recurrent heart failure events. Overall, 60.9% of patients had BMI ≥30 kg/m 2.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

Circulation

OCTOBER 13, 2023

BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Rates of the primary outcome were 8.7 Circulation, Volume 148, Issue 24 , Page 1945-1957, December 12, 2023.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Hypertension Myocardial Infarction 40

The British Journal of Cardiology

JULY 17, 2024

2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”

Kidney Disease 52

Kidney Disease Outcomes Diabetes Heart Failure 52

American College of Cardiology

APRIL 10, 2024

What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?

Preserved Ejection Fraction 60

Preserved Ejection Fraction Obesity Heart Failure Diabetes 60

Frontiers in Cardiovascular Medicine

JANUARY 15, 2024

This systematic review of the literature aims to explore outcomes in the patients treated with conservative management vs. invasive strategy. The overall prevalence of arterial hypertension was 33.2%, hyperlipidemia, 26.9%, smoking, 17.8%, and diabetes, 3.9%. The overall mean age was 49.12 +/− 3.41, and 88% were females.

SCAD 75

SCAD Coronary Artery Bypass Graft Outcomes Myocardial Infarction 75

European Journal of Heart Failure

OCTOBER 9, 2023

COVID-19, coronvirus disease-2019; HF, heart failure. Aim COVID-19 may affect clinical risk in patients with heart failure. This study aimed to evaluate the association between COVID-19 and clinical outcomes among DELIVER participants. DELIVER began before and was conducted during the COVID-19 pandemic.

Preserved Ejection Fraction 40

Preserved Ejection Fraction COVID-19 Heart Failure Hospital 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

IntroductionThere is a higher prevalence of diabetes mellitus type 2 in Hispanics as compared to other ethnic groups in the United States. Diabetes is a risk factor for acute ischemic stroke and also a poor predictor of outcome for many interventional surgeries. or greater. vs. 20.5%; p = 0.048) and stenting (28.4%

Outcomes 40

Outcomes Angioplasty Atrial Fibrillation Diabetes 40

Circulation: Cardiovascular Quality & Outcomes

FEBRUARY 8, 2024

Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. Background:Heart failure (HF) affects >6 million US adults, with recent increases in HF hospitalizations. Heterogeneity by diabetes was assessed using an interaction term.Results:The mean age was 64.4 had diabetes. were Black adults, 54.9%

Heart Failure 40

Heart Failure Stroke Strokes Diabetes 40

Open Heart

JULY 20, 2022

Aims Heart failure (HF) is associated with comorbidities which independently influence treatment response and outcomes. Methods Patients acted as their own controls, with outcomes compared for equal periods (for each patient) pre (HF MDT) versus post-MDT (multispecialty) meeting. Results 334 patients (mean age 72.5±11

Heart Failure 52

Heart Failure Kidney Disease Outpatient Nursing 52

European Journal of Heart Failure

OCTOBER 4, 2023

Treatment effect by number of NCCs ( C ), with test of interaction for the outcome. CI, confidence interval; COPD, chronic obstructive pulmonary disease; HF, heart failure; HR, hazard ratio; TIA, transient ischaemic attack. Average percentage of the optimal doses of GDMTs by number of NCCs ( B ).

Heart Failure 40

Heart Failure Hospital Quality of Life Pulmonary 40

CardiacWire

JANUARY 7, 2024

Applied Therapeutics saw its shares fall 40% late last week after revealing that its diabetic cardiomyopathy drug candidate AT-001 (caficrestat) didn’t meet its phase 3 trial’s primary endpoint. AT-001 is an investigational oral Aldose Reductase inhibitor being developed for the treatment of diabetic cardiomyopathy.

Cardiomyopathy 59

Cardiomyopathy Diabetes Cardiac Function Heart Failure 59

Heart BMJ

MAY 10, 2024

Hospitalisation due to this condition is exponentially growing, and now outnumbers those for both heart failure and myocardial infarction. Arrhythmia prediction models have long relied on conventional risk factors such as age, diabetes, hypertension, and history of myocardial infarction and heart failure.

Arrhythmia 40

Arrhythmia Myocardial Infarction Heart Failure Atrial Fibrillation 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

IntroductionCardiomyopathy (CM) is a diverse pathology defined by both structural and functional changes in the heart. Outcome measures studied included prolonged length of stay (LOS), discharge disposition, and inpatient mortality.ResultsWe identified 2,939,160 patients with AIS between 2016 and 2019. 16.4%, p < 0.001).

Heart Failure 40

Heart Failure Cardiomyopathy Inpatient Stroke 40

European Journal of Heart Failure

DECEMBER 12, 2023

Abstract Objectives This study aimed to assess the impact of anemia and iron deficiency (ID) on clinical outcome in patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI). Nevertheless, data concerning the impact of anemia and ID on clinical outcome in patients with CS are scarce.

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Outcomes Catheterization Laboratory 40

Cardiology Update

JULY 22, 2024

This multicenter open-label, blinded-outcome, randomized trial ( NCT04030234 ), offers new insights into hypertension management. The primary outcome measured was a composite of myocardial infarction, revascularisation, hospitalisation for heart failure, stroke, or cardiovascular death, assessed over a median follow-up of 3.4

Blood Pressure 52

Blood Pressure Myocardial Infarction Diabetes Hypertension 52

Journal of the American Heart Association

JANUARY 31, 2024

The primary efficacy end point was the composite of cardiovascular death and hospitalizations for heart failure. The secondary efficacy end points were all‐cause death, cardiovascular death, hospitalizations for heart failure, kidney disease progression, and acute kidney injury.

Kidney Disease 40

Kidney Disease Heart Failure Diabetes Outcomes 40

Circulation

NOVEMBER 11, 2023

Background:Sodium glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone all individually reduce cardiovascular, kidney and mortality outcomes in patients with type 2 diabetes and albuminuria. years compared to 17.9

Diabetes 40

Diabetes Myocardial Infarction Heart Failure Risk Factors 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 5, 2023

Abstract Introduction Influence of early atrial fibrillation (AF) ablation, particularly cryoballoon ablation (CBA), on clinical outcome during long-term follow-up has not been clarified. The primary outcome was recurrence of atrial tachyarrhythmias (ATs) of ≥30-s after a 3-month blanking period.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Kidney Disease 40

Journal of the American Heart Association

DECEMBER 29, 2023

AF increases the risk of stroke, heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. ABSTRACTAtrial fibrillation (AF) is the most common cardiac arrhythmia.

Obesity 45

Obesity Atrial Fibrillation Heart Failure Dementia 45

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

European Journal of Heart Failure

FEBRUARY 12, 2024

CI, confidence interval; EDMi, end-diastolic mass index; HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction. Participants with the worst GLS (Q4) were more likely male and of the Black race with a history of tobacco use and diabetes with lower LVEF, higher LV end-diastolic volume, and higher LV mass index.

Cardiovascular Disease 40

Cardiovascular Disease Biomarkers Myocardial Infarction Heart Failure 40

Science Daily - Heart Disease

FEBRUARY 16, 2024

Researchers analyzed more than 145 million records covering every adult patient admitted to hospital in England over a nine-year period to establish the risk of long-term health outcomes following a heart attack -- in the largest study of its kind.

Heart Attack 43

Heart Attack Heart attacks Peripheral Arterial Disease Atrial Fibrillation 43

Cardiometabolic Health Congress

AUGUST 8, 2024

Cardiometabolic risk encompasses a complex spectrum of interrelated conditions, including cardiovascular disease, type 2 diabetes, and metabolic syndrome. This blog post explores the development of such partnerships and their potential to transform healthcare outcomes.

Education 59

Education Kidney Disease Diabetes Cardiovascular Disease 59

DAIC

FEBRUARY 29, 2024

This year’s theme, “Advancing Cardiovascular Care for All” brings the latest practice-changing breakthroughs, along with top experts debating and discussing outcomes of highly-anticipated clinical trials. 24 from April 6 - 8, 2024 in Atlanta, GA at the Georgia World Congress Center.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

DAIC

SEPTEMBER 11, 2024

A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. Earlier projections had estimated that 3.3 million U.S. The study appears Sept. 11 in the Journal of the American College of Cardiology JACC.

Atrial Fibrillation 52

Atrial Fibrillation Quality of Life Myocardial Infarction Kidney Disease 52

Cardiometabolic Health Congress

AUGUST 30, 2024

Cardiometabolic diseases, encompassing cardiovascular conditions and metabolic disorders like diabetes, are among the most widespread global health challenges. Coronary Heart Disease : Initiate beta-blockers in patients with acute MI and normal LVEF unless contraindicated or if they have heart failure.

Cardiac Rehabilitation 52

Cardiac Rehabilitation Heart Failure Quality of Life Aortic 52

Journal of the American Heart Association

JANUARY 19, 2024

BackgroundThis study evaluated the effects of canagliflozin in patients with type 2 diabetes with and without prevalent cardiovascular disease (secondary and primary prevention).Methods

Kidney Disease 40

Kidney Disease Diabetes Heart Failure Cardiovascular Disease 40